[
  {
    "question": "child has 3 weeks history of lower limbs weakness MRI spine: T4 and T8 intramedullary irregular non enhanced lesion, diagnosis:",
    "option_a": "Astrocytoma",
    "option_b": "Ependymoma",
    "option_c": "GBM",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Intramedullary spinal cord tumors in children, particularly those causing progressive weakness of the lower limbs, are most commonly astrocytomas. These tumors originate from astrocytes within the spinal cord parenchyma and display characteristic imaging features that help differentiate them from other intramedullary lesions. Spinal cord astrocytomas arise due to abnormal proliferation of astrocytes. They tend to be infiltrative, ill-defined, and can involve multiple segments of the spinal cord. Their irregular margins and lack of robust enhancement on MRI are in part due to their infiltrative nature and lower vascularity compared with other tumor types. The clinical presentation in children often includes slowly progressive motor weakness, sensory disturbances, and sometimes pain. The described MRI findings of T4 and T8 intramedullary irregular, non-enhancing lesions are more consistent with an astrocytic neoplasm rather than a well-circumscribed, enhancing lesion like an ependymoma. MRI is the investigation of choice for intramedullary spinal lesions. Differential diagnoses include ependymomas, which are typically more well-demarcated and show homogeneous enhancement, and very rarely spinal cord glioblastoma multiforme (GBM), which is highly aggressive and uncommon in children. Inflammatory or demyelinating lesions should also be considered, but the chronicity and imaging features favor a neoplastic process. The treatment approach is tiered: First-line management involves surgical resection when safely possible. For tumors that are infiltrative and not easily resectable, adjuvant therapies including radiotherapy may be considered, keeping in mind the long-term risks in children. In pediatric patients, preserving neurological function is paramount, and multidisciplinary management is key. In pregnant patients, the timing and modality of treatment require careful planning to balance maternal benefit with fetal safety; radiation and surgery are generally delayed if possible unless there is rapid neurological decline. Option A (Astrocytoma) is correct because the clinical scenario of an intramedullary, irregular, non-enhancing lesion in a child fits the profile of a spinal astrocytoma. Option B (Ependymoma) is less likely as these tumors are usually more well-circumscribed with homogeneous enhancement. Option C (GBM) is exceedingly rare in the spinal cord of children and would present with a more aggressive course. 1. Pediatric intramedullary tumors are most commonly astrocytomas. 2. The irregular, non-enhancing nature on MRI supports an infiltrative astrocytic process over a well-demarcated ependymal tumor. Recent studies have emphasized the importance of early diagnosis and the role of molecular markers in guiding treatment. Current guidelines suggest maximal safe resection followed by adjuvant therapy when indicated, with a strong emphasis on preserving neurological function in the pediatric population.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Same scenario, what is the most appropriate tool for investigation in this patient?",
    "option_a": "Brain MRI with gadolinium",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Brain MRI with gadolinium is the imaging method of choice when evaluating suspected intracranial pathology. The use of the gadolinium contrast agent helps delineate lesions by highlighting areas of blood\u2013brain barrier disruption, which is common in tumors, inflammatory lesions, and infections. In many intracranial diseases, the blood\u2013brain barrier becomes disrupted. Gadolinium, a paramagnetic contrast agent, leaks into these regions and shortens the T1 relaxation time on MRI, making the affected areas appear hyperintense. This enhancement aids in the characterization of lesions (e.g., differentiating active tumor margins from surrounding edema). When patients present with neurological symptoms raising concern for an intracranial process (such as focal neurologic deficits, altered mental status, or signs of increased intracranial pressure), a detailed and sensitive investigation is required. MRI with gadolinium provides both high resolution and contrast detail, critical in diagnosing conditions like neoplasms, multiple sclerosis, or infectious processes. Differential diagnoses in such scenarios include primary brain tumors, metastases, demyelinating lesions, and abscesses. MRI with gadolinium is preferred over CT because of its superior soft tissue contrast and ability to detect smaller or non-calcified lesions. In some emergencies, a CT scan may be performed initially; however, for detailed evaluation, MRI is superior. First-line management in suspected intracranial pathology involves prompt neuroimaging. According to current guidelines, when a lesion is suspected the next appropriate step is to obtain an MRI with contrast. Should the patient be pregnant or lactating, risk\u2013benefit discussions become paramount; current guidelines suggest that gadolinium crosses the placenta and should be avoided unless absolutely essential. In such cases, MRI without contrast may be considered initially, or alternative modalities may be weighed based on clinical urgency. Option A (Brain MRI with gadolinium) is correct because it is the most sensitive and specific tool for evaluating many intracranial pathologies. The other options were not provided, but none would typically supersede MRI with contrast in this scenario. 1. Gadolinium enhancement on MRI is key to identifying lesions with a disrupted blood\u2013brain barrier. 2. Brain MRI is superior to CT scan for delineating soft tissue details in suspected neurological conditions. 3. Always consider patient-specific factors such as pregnancy when selecting imaging modalities. Recent clinical guidelines and research emphasize the role of MRI with gadolinium as the investigation of choice for many neurological conditions due to its high sensitivity and resolution. Studies and consensus guidelines from neuroradiology societies reinforce its use particularly when detailed lesion characterization is needed.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "A 44-year-old woman is evaluated for severe and progressive left shoulder pain radiating down to the left arm and forearm that started 5 weeks ago. Since then, she has developed left hand weakness and numbness in the fourth and fifth fingers. She has a history of localized left breast adenocarcinoma that was diagnosed 5 years ago and treated with lumpectomy and axillary node dissection followed by radiation therapy and chemotherapy, including paclitaxel. Examination shows anisocoria with the left pupil smaller than the right, mild left eyelid ptosis, weakness in intrinsic left hand muscles, and sensory loss in the left medial arm, forearm, and fourth and fifth fingers. Reflexes are normal. The rest of her neurologic examination is normal. Which of the following is the most likely diagnosis?",
    "option_a": "carcinomatous meningitis",
    "option_b": "cervical radiculopathy due to epidural metastasis",
    "option_c": "neoplastic plexopathy",
    "option_d": "paraneoplastic plexopathy",
    "option_e": "radiation plexopathy",
    "correct_answer": "C",
    "subspecialty": "Neuro-oncology",
    "explanation": "Neoplastic plexopathy refers to the involvement of the brachial plexus by malignant cells. In patients with a history of cancer, especially breast cancer, new-onset severe, painful plexopathy is highly suggestive of tumor recurrence or local invasion. Tumor infiltration of the brachial plexus leads to direct damage and compression of nerve fibers. This invasion particularly affects the lower elements of the plexus (C8-T1), which can also involve adjacent sympathetic fibers, resulting in signs such as Horner\u2019s syndrome (ptosis and miosis). The pain is usually severe and rapidly progressive due to the aggressive nature of malignant infiltration. The patient\u2019s history of breast adenocarcinoma, combined with severe shoulder pain radiating to the arm, intrinsic hand muscle weakness, sensory deficits in the medial arm and hand (especially the fourth and fifth fingers), and signs of Horner\u2019s syndrome, all point towards a neoplastic process rather than a benign or post-treatment complication like radiation plexopathy. Differential diagnoses include carcinomatous meningitis, cervical radiculopathy from epidural metastasis, paraneoplastic plexopathy, and radiation-induced plexopathy. Neoplastic plexopathy is differentiated by its intense pain, rapid progression, and involvement of the sympathetic chain (resulting in Horner\u2019s syndrome). MRI of the brachial plexus and PET imaging may be used for further localization and confirmation. First-line management includes confirming the diagnosis with imaging (MRI of the brachial plexus) and possibly a biopsy. Treatment generally involves multidisciplinary management with oncologic therapies such as chemotherapy, radiation, and, in selected cases, surgical intervention or nerve pain management. While pregnancy and lactation considerations are less typical in a middle-aged woman with breast cancer history, treatment plans should always be individualized with a view to potential hormonal or teratogenic effects if relevant. Option A (carcinomatous meningitis) typically presents with diffuse multifocal neurological deficits and not a localized plexus process. Option B (cervical radiculopathy due to epidural metastasis) would primarily produce a radicular pattern, often without involvement of the sympathetic chain. Option D (paraneoplastic plexopathy) is usually less painful and often symmetric. Option E (radiation plexopathy) tends to present after a shorter interval post-radiation and typically spares the sympathetic fibers; the presence of Horner\u2019s syndrome strongly favors neoplastic infiltration. Therefore, option C (neoplastic plexopathy) is the most likely diagnosis. 1. A history of breast cancer with new-onset painful brachial plexopathy should immediately raise suspicion for tumor recurrence. 2. Horner\u2019s syndrome is a red flag suggesting involvement of the lower brachial plexus and adjacent sympathetic chain. 3. Always differentiate between radiation-induced and neoplastic plexopathy based on pain severity, timing, and associated neurological signs. Latest research and clinical guidelines support the use of advanced imaging techniques like MRI and PET scans for accurately diagnosing neoplastic brachial plexopathy. Current evidence underscores the aggressive nature of malignant plexopathies and the need for timely, multidisciplinary intervention to manage pain and halt progression.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Mees line? Arsenic",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Arsen",
    "subspecialty": "Neuro-oncology",
    "explanation": "Mees\u2019 lines are transverse white bands that appear on the nails and are classically associated with heavy metal poisoning, particularly arsenic. They result from the temporary disruption in nail matrix keratinization. Arsenic poisoning interferes with cellular metabolism and keratin synthesis in the nail matrix, resulting in the formation of distinct white transverse streaks, known as Mees\u2019 lines. This manifestation is considered pathognomonic for arsenic exposure when correlated with systemic findings of toxicity. Patients with arsenic poisoning may present with gastrointestinal symptoms (nausea, vomiting, abdominal pain), peripheral neuropathy, and specific dermatologic findings including hyperpigmentation and Mees\u2019 lines. Recognition of these nail changes should prompt evaluation for heavy metal toxicity. The differential diagnosis for nail changes includes Beau\u2019s lines (which are depressions in the nails associated with systemic illnesses or chemotherapy), thallium poisoning (which also features alopecia and painful neuropathy), and lead poisoning (associated with Burton\u2019s lines on the gums rather than Mees\u2019 lines). Laboratory assays to measure arsenic levels confirm the diagnosis. Management involves immediate removal from the source of exposure and initiating chelation therapy with agents such as dimercaprol or succimer. In the context of pregnancy or lactation, careful selection of chelation agents is critical because some chelators can cross the placenta; guidelines recommend using agents with the best safety profile after weighing maternal and fetal risks. The analysis indicates that arsenic is the correct association for Mees\u2019 lines. Thallium poisoning may cause similar nail changes but is more typically associated with alopecia and severe neuropathy. Chemotherapy agents can cause Beau\u2019s lines rather than Mees\u2019 lines, and lead poisoning has distinct clinical features like Burton\u2019s line on the gums. Therefore, arsenic is uniquely correlated with Mees\u2019 lines. 1. Mees\u2019 lines are a key clinical sign of arsenic poisoning and should prompt further toxicological investigation. 2. A careful history regarding potential environmental or occupational exposures is crucial when these nail changes are observed. 3. Early intervention with chelation therapy is essential to minimize systemic toxicity. Recent toxicology literature continues to emphasize the diagnostic significance of Mees\u2019 lines in arsenic poisoning. Current guidelines advocate for prompt chelation therapy and supportive care as essential components in the management of heavy metal toxicity, including careful consideration in pregnant or lactating patients.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Boy with Headache more in the morning associated with N/V what to do next",
    "option_a": "CT brain",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Morning headaches associated with nausea and vomiting in a child are red-flag symptoms that suggest raised intracranial pressure, often due to a space-occupying lesion such as a brain tumor. Intracranial space-occupying lesions, like tumors, can cause increased intracranial pressure which is often most pronounced in the morning due to overnight cerebral edema and recumbency. This pressure can trigger nausea and vomiting through the pressure on brainstem centers that mediate emesis. A boy presenting with headaches that are worse in the morning and associated with nausea and vomiting raises immediate concern for conditions causing raised intracranial pressure. This presentation necessitates urgent neuroimaging to identify potentially life-threatening intracranial pathology. Differential diagnoses include migraine, tension-type headache, and sinusitis; however, the red flag of morning predominance and vomiting makes an intracranial mass the leading concern. In an acute setting, a CT brain is performed first for rapid evaluation of intracranial hemorrhage, mass lesions, or hydrocephalus. MRI is more sensitive but is not as readily available in emergency settings. First-line management for a child with red flag symptoms is rapid neuroimaging. A non-contrast CT scan is typically the initial investigation because of its wide availability and speed, particularly in emergency settings. If the CT scan suggests an abnormality, further detailed imaging with MRI may follow. In pediatric patients, radiation exposure is a concern; hence, if the clinical situation allows, MRI can be considered if there is no acute threat. In pregnant or lactating patients (though not applicable in this boy), imaging protocols would require careful consideration of radiation risks and the use of shielding or alternative modalities. Option A (CT brain) is the correct initial investigation in this clinical scenario because it is fast, widely available, and effective for detecting acute intracranial abnormalities. The other options were not listed, but modalities such as MRI, while more detailed, are usually reserved for follow-up evaluation once the acute situation has been addressed. 1. Morning headache with nausea and vomiting in children is a red flag for increased intracranial pressure, prompting urgent imaging. 2. CT brain is the first-line imaging study in an emergency due to its speed and availability. 3. Early detection of intracranial mass lesions significantly impacts overall prognosis and management. Recent clinical guidelines for pediatric headache management stress the importance of neuroimaging when red-flag symptoms are present. CT scanning remains the cornerstone in emergency settings for rapid assessment, with MRI serving as a complementary tool for further characterization of lesions once an abnormality is detected.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Brain MRI showing mass originating from fourth ventricle Histology showing pseudorosette",
    "option_a": "ependymoma",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Ependymoma is a glial tumor that commonly arises from ependymal cells lining the ventricular system, especially the fourth ventricle in pediatric and young adult populations. This lesion is often characterized radiographically by its location and histologically by the presence of perivascular pseudorosettes. Ependymomas develop from the ependymal lining of the ventricles and spinal canal. The formation of perivascular pseudorosettes, where tumor cells radially arrange around blood vessels, is a hallmark of the tumor\u2019s growth pattern. Recent molecular analyses have further subclassified ependymomas based on genetic mutations and location, which can influence prognosis and management. Patients may present with symptoms of increased intracranial pressure, such as headache, nausea, or vomiting, often secondary to obstructive hydrocephalus from fourth ventricle involvement. The location and growth pattern of the tumor correlate closely with these clinical findings. Diagnosis is typically made with brain MRI, which reveals a mass in the fourth ventricle. Differential diagnoses include medulloblastoma (especially in children), choroid plexus papilloma, and brainstem glioma. Histopathological analysis is essential, with the identification of pseudorosette formations confirming the diagnosis of ependymoma. The standard first-line treatment for ependymoma is maximal safe surgical resection. Postoperative radiotherapy is considered, especially in cases of incomplete resection or anaplastic variants. Chemotherapy has a more limited role. In pregnant and lactating women, treatment decisions require a multidisciplinary approach balancing maternal benefit and fetal/neonatal safety, with surgery typically deferred to the second trimester when possible and radiotherapy planned postpartum if feasible. Option A (ependymoma) is correct because the imaging localization (fourth ventricle) and the histological finding of pseudorosettes are classic for ependymoma. Other potential options not provided would include lesions that do not typically show pseudorosette formation or arise from other tissues. 1) Ependymomas are one of the few brain tumors with a predilection for the fourth ventricle. 2) The presence of perivascular pseudorosettes on histopathology is a key diagnostic feature. 3) Maximal safe resection is crucial for optimal outcomes. Recent research emphasizes the importance of molecular profiling in ependymomas, which has led to updated risk stratification and management guidelines. Multimodal treatment approaches continue to be refined, with growing data supporting the role of adjuvant radiotherapy in cases with residual tumor.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_27.png"
  },
  {
    "question": "In which of the following dexamethasone helping",
    "option_a": "Tumor with vasogenic edema",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Dexamethasone is a potent corticosteroid used in neurology primarily to reduce cerebral edema. Its role is particularly prominent in managing vasogenic edema associated with brain tumors, where edematous changes can exacerbate neurological symptoms. Vasogenic edema results from disruption of the blood-brain barrier, leading to extravasation of plasma proteins and fluid into the extracellular space. Dexamethasone works by stabilizing the vascular endothelium, reducing permeability, and thereby decreasing the extent of edema. In the setting of brain tumors, vasogenic edema can significantly contribute to increased intracranial pressure, resulting in headaches, nausea, and focal neurological deficits. Administration of dexamethasone helps alleviate these symptoms by reducing peritumoral swelling. Assessment of a patient with brain tumor symptoms often includes MRI, which will show areas of edema around the tumor. The differential includes differentiating vasogenic edema from cytotoxic edema (such as in ischemic stroke), where corticosteroids are not beneficial. The first-line management of vasogenic edema in brain tumors generally involves corticosteroids like dexamethasone. Doses and duration depend on clinical response and potential side effects. In pregnant patients, the risks and benefits must be carefully weighed because steroids can cross the placenta; however, when indicated, they are used with caution. In lactating women, small amounts are excreted in breast milk, so alternative strategies or temporary cessation might be considered if high doses are required. Option A is correct because dexamethasone is especially beneficial in managing tumor-associated vasogenic edema. Other options might discuss alternative edema types or different indications where dexamethasone is less effective. 1) Dexamethasone is the corticosteroid of choice for treating vasogenic edema in brain tumors. 2) It improves neurological symptoms by reducing intracranial pressure. 3) Caution is warranted in pregnant and lactating patients due to potential effects on the fetus or neonate. Current neuro-oncology guidelines continue to endorse dexamethasone for vasogenic edema. Ongoing research is focused on optimizing dosing schedules to minimize side effects while achieving effective symptom control.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Coronal brain MRI showing frontal extra axial homogeneous mass, Histopathology?",
    "option_a": "Psammoma bodies",
    "option_b": "Pseudopalisading",
    "option_c": "Neovascularization",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "A homogeneous, extra-axial mass in the frontal region on MRI is strongly suggestive of a meningioma. Meningiomas arise from the meninges and are typically benign, with a high incidence in middle-aged women. Histopathology often reveals psammoma bodies, which are calcified whorls seen in many meningiomas. Meningiomas develop from arachnoid cap cells in the dura mater. The slow-growing nature of these tumors allows calcifications to form over time, leading to the characteristic psammoma bodies on microscopic examination. Hormonal influences, particularly progesterone, may also play a role in tumor pathogenesis. Patients with meningiomas may be asymptomatic or present with symptoms due to mass effect, such as headaches or focal neurological deficits. The extra-axial location and dural attachment on imaging further support the diagnosis of meningioma. The diagnosis is primarily made on imaging with MRI or CT, which typically shows an extra-axial, well-circumscribed, and uniformly enhancing mass often associated with a dural tail. Differential diagnoses include schwannomas (usually associated with cranial nerves), metastases, and other extra-axial tumors. Histopathological confirmation via biopsy, showing psammoma bodies, clinches the diagnosis. Management of meningiomas depends on their size, location, and symptomatology. For symptomatic lesions, the first-line treatment is surgical resection, which is often curative. Radiotherapy is reserved for recurrences or for lesions that are surgically inaccessible. In pregnant or lactating patients, conservative management is preferred if the tumor is asymptomatic, as hormonal changes may influence tumor growth; however, treatment timing should consider fetal and neonatal safety. Option A (psammoma bodies) is correct because these calcified structures are a classic histopathological finding in meningiomas. Option B (pseudopalisading) is typically associated with glioblastoma, and option C (neovascularization) is more characteristic of high-grade gliomas, not meningiomas. 1) Meningiomas are the most common benign intracranial tumors, especially in women. 2) The presence of a dural tail on imaging is highly suggestive of a meningioma. 3) Psammoma bodies on histology help confirm the diagnosis. Latest guidelines emphasize the role of imaging characteristics and histopathological analysis in the management of meningiomas. Recent studies also highlight the potential hormone receptor expression in these tumors, which may influence future targeted therapies.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_27.png"
  },
  {
    "question": "Next step\na) Surgery\nb) Reassurance\nc) Radiotherapy\nd) Yearly MRI\n(I think it was incidental finding with no symptoms or just minimal headache)",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "(yearly MRI) is the correct choice because structured surveillance is the recommended strategy for incidental lesions. Option A (surgery) and Option C (radiotherapy) are overly aggressive for benign, stable lesions, while Option B (reassurance without follow\u2010up) fails to provide adequate monitoring to detect any future changes.",
    "option_e": "",
    "correct_answer": "d",
    "subspecialty": "Neuro-oncology",
    "explanation": "Incidental intracranial tumors, especially when asymptomatic or producing minimal symptoms such as a mild headache, are often managed conservatively. The concept is to avoid overtreatment and mitigate potential intervention-related risks. Many incidental tumors are slow-growing and not immediately life-threatening. Their natural history allows for a period of observation with serial imaging, during which any significant changes in size or characteristics can prompt intervention. In patients with incidental findings on imaging who are asymptomatic or minimally symptomatic, aggressive treatments like surgery or radiotherapy may cause unnecessary harm. Symptoms, if they arise, usually occur only when there is tumor growth or a change in behavior. Differential diagnosis for incidental brain lesions includes benign tumors such as meningiomas, low-grade gliomas, or other non-neoplastic processes like developmental venous anomalies. Serial imaging, typically with MRI, helps differentiate stable lesions from those that are progressive. According to current neuro-oncology guidelines, the first approach for an incidental, asymptomatic tumor is active surveillance with periodic imaging, for example, yearly MRI. Surgery is reserved for symptomatic or progressive tumors, and radiotherapy is considered only when lesions are unresectable or have recurred. In pregnant patients, the approach is even more conservative due to fetal safety concerns, with MRI being preferred over CT when possible (and without gadolinium unless absolutely necessary). Lactating women are managed similarly, with careful consideration of the risks and benefits of any intervention. Option D (yearly MRI) is the correct choice because structured surveillance is the recommended strategy for incidental lesions. Option A (surgery) and Option C (radiotherapy) are overly aggressive for benign, stable lesions, while Option B (reassurance without follow\u2010up) fails to provide adequate monitoring to detect any future changes. 1) Most incidental brain tumors, particularly if asymptomatic, are managed with regular imaging follow-up. 2) Immediate intervention is reserved for lesions that are symptomatic or show radiographic progression. 3) Conservative management minimizes procedural risks in otherwise stable patients. Recent guideline updates in neuro-oncology advocate for a conservative management strategy for incidental brain tumors, emphasizing the importance of serial imaging to guide treatment decisions. Emerging research continues to support observation for small, asymptomatic lesions to avoid unnecessary morbidity.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Histopathology for the attached MRI:",
    "option_a": "(Pseudopalisading necrosis) is correct because it directly correlates with the GBM pathology. Option b (Pseudorosette) is typically seen in ependymomas. Option c (Fried egg) describes the morphology found in oligodendrogliomas, and option d (Psammoma bodies) is a feature of meningiomas.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-oncology",
    "explanation": "Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor. Its core defining feature is the rapid proliferation of atypical astrocytic cells combined with areas of necrosis. The pseudopalisading necrosis\u2014where tumor cells line up around necrotic zones\u2014is the histopathological hallmark of GBM. GBM develops through a series of genetic mutations (e.g., EGFR amplification, PTEN loss, p53 mutations) that drive rapid growth and angiogenesis. Because the tumor grows so quickly, central areas become hypoxic and necrotic. The surviving tumor cells then orient themselves around these necrotic foci, creating the classic pseudopalisading pattern seen under the microscope. Patients with GBM typically present with symptoms such as headaches, seizures, and focal neurological deficits depending on the tumor\u2019s location. On MRI, GBM classically appears as irregular, ring\u2010enhancing lesions due to central necrosis and blood\u2013brain barrier disruption, which correlates with the histological picture of pseudopalisading necrosis. The diagnosis of GBM requires correlation of imaging and histopathology. Differential diagnoses include brain abscess (which may also form ring-enhancing lesions), metastases, or other high-grade glial tumors. Definitive diagnosis is achieved through biopsy and histopathological analysis showing pseudopalisading necrosis, microvascular proliferation, and cellular atypia. Management involves maximal safe surgical resection followed by radiotherapy with concomitant and adjuvant temozolomide chemotherapy. In special scenarios such as pregnancy or lactation, therapy must be individualized: for instance, radiotherapy and temozolomide require careful risk\u2013benefit analysis as these therapies can adversely impact the fetus or breastfeeding infant. Multidisciplinary teams are critical in tailoring treatment decisions in such cases. Option a (Pseudopalisading necrosis) is correct because it directly correlates with the GBM pathology. Option b (Pseudorosette) is typically seen in ependymomas. Option c (Fried egg) describes the morphology found in oligodendrogliomas, and option d (Psammoma bodies) is a feature of meningiomas. 1. Pseudopalisading necrosis is pathognomonic for GBM. 2. Ring-enhancing lesions on MRI with central necrosis strongly suggest a high-grade glioma. 3. Early, aggressive management is essential because GBM has a rapid, invasive course. Recent guidelines such as those from the European Association of Neuro-Oncology (EANO) support the combined modality treatment (surgery, radiotherapy, and temozolomide) for GBM. Ongoing research on immunotherapy and targeted gene therapy continues to evolve in an effort to improve outcomes.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_36.png"
  },
  {
    "question": "Histopathology for the attached MRI:",
    "option_a": "(Pseudopalisading necrosis) is correct, correlating with the classic GBM histology. Option b (Pseudorosette) pertains to ependymomas, option c (Fried egg) indicates oligodendroglioma, and option d (Psammoma bodies) is typical for meningiomas.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-oncology",
    "explanation": "Glioblastoma multiforme (GBM) is identified by a set of distinct histopathological features, of which the pseudopalisading necrosis is most characteristic. This pattern underscores the aggressive biological behavior of the tumor. In GBM, rapid tumor growth outpaces its blood supply, causing central areas of necrosis. The tumor cells form dense bands (pseudopalisades) around these necrotic zones as a reactive pattern to hypoxia. Molecular alterations such as EGFR amplification, PTEN loss, and p53 inactivation contribute to its malignant phenotype. Patients with GBM often present with non-specific symptoms such as headaches, seizures, and focal deficits depending on tumor localization. MRI findings typically reveal irregular, ring-enhancing lesions with central necrosis, which mirror the microscopic findings of pseudopalisading necrosis. The workup of a suspected GBM includes detailed neuroimaging followed by a biopsy for histological confirmation. Differential diagnoses include brain metastases, abscesses, and other high-grade gliomas. The detection of pseudopalisading necrosis on histology confirms the diagnosis of GBM. The standard approach to GBM includes aggressive surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide chemotherapy. In pregnant or lactating patients, treatment protocols must balance the aggressiveness of the tumor with risks to the fetus or infant, often requiring modifications or delays in therapy, and should involve a multidisciplinary team. Option a (Pseudopalisading necrosis) is correct, correlating with the classic GBM histology. Option b (Pseudorosette) pertains to ependymomas, option c (Fried egg) indicates oligodendroglioma, and option d (Psammoma bodies) is typical for meningiomas. 1. GBM\u2019s rapid growth is reflected by its distinctive histology of pseudopalisading necrosis. 2. MRI ring-enhancement with central necrosis is highly suspicious for GBM. 3. Multimodal treatment is critical for managing this aggressive tumor, despite its generally poor prognosis. Current therapeutic guidelines (e.g., EANO, NCCN) emphasize maximal safe resection followed by radiotherapy plus temozolomide. Novel approaches, including tumor-treating fields and immunotherapy, are under investigation to improve patient outcomes.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_36.png"
  },
  {
    "question": "Dexamethasone best for\na) Vasogenic edema  b) Cytotoxic edema  c) HTN  d) Liver encephalopathy",
    "option_a": "(Vasogenic edema) is correct because dexamethasone specifically targets the pathophysiological mechanisms of vasogenic edema. Option b (Cytotoxic edema) is incorrect since it stems from intracellular fluid accumulation due to cellular metabolic failure. Options c (Hypertension) and d (Liver encephalopathy) have entirely different etiologies and are managed by other, non",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-oncology",
    "explanation": "Dexamethasone is a potent corticosteroid commonly used in neurology to reduce inflammation and edema, specifically vasogenic edema, which frequently accompanies brain tumors and other CNS pathologies. Vasogenic edema arises from disruption of the blood\u2013brain barrier, allowing fluid and plasma proteins to accumulate in the extracellular spaces of the brain. Dexamethasone works by stabilizing capillary membranes and reducing inflammatory cytokines, thereby decreasing the permeability that leads to edema. Clinically, vasogenic edema can lead to increased intracranial pressure, resulting in symptoms such as headache, nausea, and altered mental status. Dexamethasone effectively reduces such edema, alleviating these clinical symptoms. The distinction between vasogenic and cytotoxic edema is essential. Whereas vasogenic edema (often seen with tumors, abscesses, and trauma) responds well to corticosteroids, cytotoxic edema\u2014which results from cell death such as in ischemic stroke\u2014does not benefit from steroid therapy. Differential diagnoses include hypertensive encephalopathy and hepatic encephalopathy, conditions with distinct underlying mechanisms. First-line management of tumor-associated vasogenic edema is with corticosteroids such as dexamethasone. In patients who are pregnant or lactating, the use of steroids requires careful dosing and risk\u2013benefit evaluation due to potential fetal or neonatal effects, but they remain the treatment of choice when clinically indicated. Option a (Vasogenic edema) is correct because dexamethasone specifically targets the pathophysiological mechanisms of vasogenic edema. Option b (Cytotoxic edema) is incorrect since it stems from intracellular fluid accumulation due to cellular metabolic failure. Options c (Hypertension) and d (Liver encephalopathy) have entirely different etiologies and are managed by other, non-steroidal approaches. 1. Dexamethasone is most effective for vascular permeability-related edema (vasogenic). 2. It is not beneficial in cytotoxic edema where cellular injury predominates. 3. In neuro-oncology, dexamethasone helps reduce intracranial pressure and improves symptoms. Guidelines continue to support the use of dexamethasone for managing vasogenic edema, particularly in the setting of brain tumors. Recent research also emphasizes using the minimum effective dose to mitigate potential side effects, especially in vulnerable populations such as pregnant or breastfeeding women.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "40-year-old female came with chronic headache, MRI is shown (it shows frontal parasagittal enhancing lesion. what you expect to find in the brain biopsy?",
    "option_a": "(Pseudopalisading necrosis) is characteristic of glioblastoma, not meningioma, and does not align with the typical parasagittal lesion in a middle",
    "option_b": "(Pseudorosette) suggests ependymoma. Option c (Fried egg appearance) is seen in oligodendrogliomas. Option d (Psammoma bodies) is the hallmark of meningiomas, making it the correct answer in this context.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "d",
    "subspecialty": "Neuro-oncology",
    "explanation": "Meningiomas are the most common extra-axial brain tumors and are often benign. They typically arise from arachnoidal cap cells and are most frequently observed in middle-aged women. Their location is usually parasagittal, often adjacent to the dura. Meningiomas grow slowly and are characterized by a well-organized, whorled arrangement of cells. A key histopathological feature is the presence of psammoma bodies, which are concentrically laminated calcifications. These features reflect the tumor\u2019s origin and benign nature, albeit with a potential for local mass effect. A 40-year-old female presenting with chronic headache and an enhancing parasagittal lesion on MRI is most commonly suggestive of a meningioma. The chronicity of symptoms, the typical parasagittal location, and the demographic (female) strongly favor this diagnosis compared to more aggressive intra-axial tumors like GBM, which usually present with rapid deterioration. Differentials for a parasagittal enhancing lesion include meningioma, glioblastoma, and oligodendroglioma. Meningiomas are distinguished on imaging by their extra-axial location, well-circumscribed margins, and the presence of a 'dural tail'. Biopsy and histopathology revealing whorled cell patterns with psammoma bodies confirm the diagnosis. The first-line treatment for symptomatic meningiomas is surgical resection with the goal of complete removal. Adjuvant radiotherapy may be considered for residual, recurrent, or atypical/malignant meningiomas. In pregnant or lactating patients, management is guided by symptom severity; if the tumor is asymptomatic or minimally symptomatic, surgery may be deferred until after delivery, whereas symptomatic patients may require timely intervention with a multidisciplinary team approach to minimize risks. Option a (Pseudopalisading necrosis) is characteristic of glioblastoma, not meningioma, and does not align with the typical parasagittal lesion in a middle-aged woman. Option b (Pseudorosette) suggests ependymoma. Option c (Fried egg appearance) is seen in oligodendrogliomas. Option d (Psammoma bodies) is the hallmark of meningiomas, making it the correct answer in this context. 1. Meningiomas are most common in middle-aged females and typically occur in parasagittal or convexity locations. 2. The presence of a 'dural tail' on MRI and histological psammoma bodies are key diagnostic clues for meningioma. 3. Chronic headache, rather than an acute rapid decline, is more typical of a slowly growing meningioma. Current neurosurgical guidelines emphasize individualized treatment strategies for meningiomas. The role of surgery remains primary, with recent studies focusing on the outcomes of conservative versus surgical management in asymptomatic patients, as well as treatment modifications in special populations such as pregnant women.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Question of mets only to the dura and skull will happen with what of the following?",
    "option_a": "Prostate cancer",
    "option_b": "Breast cancer",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Metastases that are confined to the dura and skull are a recognized pattern seen in certain cancers. Prostate cancer, which typically produces osteoblastic (bone-forming) metastases, is known to involve the skull and adjacent dura without necessarily involving the brain parenchyma. Prostate adenocarcinoma tends to spread via Batson\u2019s venous plexus, which bypasses the pulmonary circulation and facilitates direct seeding of the vertebral column and skull. The osteoblastic nature of these lesions leads to sclerotic deposits in the skull. When these metastases extend, they may involve the dura mater, producing a pattern of metastasis that is characteristically limited to the skull and adjacent meningeal layers. Patients with skull/dural metastases from prostate cancer might present with localized headache, palpable skull lesions, or cranial nerve deficits if there is pressure on adjacent structures. The presentation can be more insidious compared to lesions that invade the brain parenchyma. Diagnosis involves imaging studies such as CT or MRI of the skull and brain. Bone scans are also useful to identify osteoblastic lesions. Differential diagnoses include metastases from breast or lung cancer, which more commonly invade brain parenchyma or present with mixed bone lesions. Radiologic characteristics (sclerotic vs. lytic lesions) help differentiate these entities. Management of prostate cancer metastases includes hormonal therapy (androgen deprivation therapy) as a first-line approach, with possible addition of chemotherapy or newer androgen receptor inhibitors in advanced cases. For localized symptomatic skull or dural metastases, external beam radiation therapy can be considered. In pregnant or lactating patients, treatment plans must weigh the risks of radiation exposure and systemic therapy against maternal benefit; multidisciplinary consultation is advised. Option A (Prostate cancer) is correct because the pattern described \u2013 metastasis solely to the dura and skull \u2013 is a recognized presentation of prostate cancer metastases due to its osteoblastic character. Option B (Breast cancer), while it can metastasize to the bone and dural surfaces, more commonly produces mixed lytic and blastic lesions and often involves parenchymal brain metastases. The missing options (C and D) are not provided but do not change the correctness of Option A. 1. Prostate cancer metastases are classically osteoblastic and can produce sclerotic skull lesions. 2. Involvement of the dura with skull lesions is a recognized pattern in prostate cancer, often linked to venous spread via Batson\u2019s plexus. Recent studies and imaging advancements have reinforced the utility of bone scintigraphy and MRI in differentiating metastatic patterns. Current guidelines emphasize the importance of integrating radiologic findings with clinical presentation and PSA levels when evaluating suspected metastatic prostate cancer.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case of cranial mets what to do?",
    "option_a": "Chest CT",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "When cranial metastases are identified, the diagnostic work-up must include an evaluation for the primary source. Since the lung is among the most common primaries for brain metastases, a chest CT is a logical and high-yield investigation. Brain metastases occur when malignant cells disseminate from a primary tumor and breach the blood-brain barrier. Lung cancer, particularly non-small cell lung cancer, is responsible for a significant proportion of brain metastases. The hematogenous spread allows tumor cells to lodge in cerebral vasculature, forming secondary deposits. Patients with brain metastases may present with headaches, focal neurological deficits, or seizures. In many instances, systemic signs or a history suggestive of lung pathology (such as chronic cough, weight loss, or smoking history) strengthen the suspicion of a pulmonary primary. A comprehensive work-up typically involves cranial imaging (MRI with contrast) to delineate the metastases and chest CT to search for a lung primary. Differential diagnoses include primary brain tumors, other metastatic lesions (from breast, melanoma, etc.), and infections (e.g., brain abscesses). The chest CT helps differentiate these by identifying characteristic lung lesions. Management of brain metastases is multidisciplinary. First-line treatment typically involves corticosteroids (to reduce vasogenic edema), followed by treatment targeted to the primary tumor (e.g., surgery, radiation therapy, systemic therapy for lung cancer). In pregnant or lactating patients, radiologic studies like CT must be used judiciously with proper shielding, and alternative imaging modalities (MRI without gadolinium, if possible) may be considered. Option A (Chest CT) is correct because, in the setting of brain metastases, the lungs are the most common source, and a chest CT is an appropriate next step in the diagnostic algorithm. The missing options (B, C, D) are not provided but do not detract from the appropriateness of the chest CT. 1. Lung cancer is the most common source of brain metastases. 2. A chest CT is essential in the work-up of patients with brain metastases to rule out a pulmonary primary. Updated guidelines and recent studies emphasize the importance of early identification of the primary tumor. The use of high-resolution CT has improved diagnostic accuracy in detecting small lung lesions, and the integration of PET-CT is increasingly common in the comprehensive work-up of metastatic cancer.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Brain lesion with pathologic description of central necrosis",
    "option_a": "GBM",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "A brain lesion described pathologically with central necrosis is highly characteristic of Glioblastoma Multiforme (GBM), the most common primary malignant brain tumor in adults. GBM is a WHO grade IV astrocytoma marked by rapid cell proliferation, incomplete vascularization, and resultant areas of hypoxia that lead to central necrosis. The histologic feature of pseudopalisading necrosis is considered almost pathognomonic for GBM, reflecting tumor cells lining up around necrotic zones. Clinically, GBM typically presents with rapid onset of focal neurological deficits, headaches, seizures, and signs of increased intracranial pressure. The aggressive nature of the tumor is consistent with its histologic appearance. Diagnosis involves neuroimaging, usually an MRI with contrast, which frequently reveals a ring-enhancing lesion with central necrosis. Differential considerations include metastatic lesions with necrosis, abscesses (though they often have a smooth rim and clinical signs of infection), and demyelinating processes. Definitive diagnosis is achieved by biopsy. The standard management of GBM involves maximal safe surgical resection followed by adjuvant radiotherapy and concomitant plus adjuvant temozolomide chemotherapy. For pregnant patients, treatment decisions are complex and must balance fetal risks (radiation, chemotherapeutic teratogenicity) with maternal prognosis; multidisciplinary management is essential. Lactating patients should be counseled regarding the excretion of chemotherapeutic agents into breast milk, and breastfeeding may be contraindicated during active treatment. Option A (GBM) is correct because the classic pathological description of central necrosis with pseudopalisading cells is most consistent with glioblastoma. Other differentials, such as abscess or metastatic lesion, typically have different clinical, radiographic, and histopathologic features. 1. GBM is notorious for its aggressive behavior and poor prognosis. 2. The presence of central necrosis with pseudopalisading cells is a key diagnostic clue for GBM. Recent clinical trials and research have stressed the importance of molecular profiling in GBM, as markers like MGMT methylation and IDH mutations guide not only prognosis but also treatment decisions. Advances such as tumor treating fields (TTF) add to the armamentarium of therapeutic options.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "In which case would steroids have an effect?",
    "option_a": "brain cancer with vasogenic edema",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Corticosteroids are effective in reducing vasogenic edema associated with brain tumors. Vasogenic edema occurs when the blood\u2013brain barrier is disrupted, leading to fluid leakage into the extracellular space, and steroids are known to stabilize the endothelial barrier. In the context of brain cancer, tumor-induced disruption of the blood\u2013brain barrier causes leakage of plasma constituents and fluid into the brain interstitium. Corticosteroids, particularly dexamethasone, decrease capillary permeability and reduce inflammation, thereby lessening the edema and its resultant mass effect. Patients with brain tumors often present with symptoms of increased intracranial pressure such as headache, nausea, and focal deficits. Administration of steroids can lead to rapid symptomatic improvement by reducing peritumoral edema. Imaging studies, primarily MRI with contrast, are used to differentiate vasogenic edema (typically surrounding tumors) from cytotoxic edema (related to infarction). The response to steroids further supports the presence of vasogenic edema as opposed to other types of cerebral swelling. Dexamethasone is the first-line corticosteroid for managing vasogenic edema associated with brain tumors. The dosing is typically tailored to the severity of symptoms, with a high initial dose followed by a gradual taper to mitigate steroid-related side effects. In pregnant or lactating patients, the benefit of using corticosteroids (especially dexamethasone, which has a lower mineralocorticoid effect) must be weighed against potential risks; however, in situations of life-threatening cerebral edema, their use is justified with appropriate counseling and monitoring. Option A (brain cancer with vasogenic edema) is correct because steroids have a proven effect in reducing vasogenic edema, which is a common accompaniment of brain tumors. Other conditions (not listed in the incomplete options) might not respond to steroids if the underlying edema is of a different type (such as cytotoxic edema in acute ischemic stroke). 1. Steroids like dexamethasone are crucial in rapidly reducing intracranial pressure due to vasogenic edema. 2. Their use is a bridging therapy to relieve symptoms while definitive treatments (surgery, radiation) are being planned. Recent guidelines continue to endorse dexamethasone as the standard of care for symptomatic management of peritumoral edema. Ongoing research focuses on optimizing dosing strategies to balance efficacy with the minimization of adverse effects, especially in sensitive populations such as pregnant or lactating patients.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "In which case would steroids have an effect?",
    "option_a": "(brain cancer with vasogenic edema) is correct because steroids effectively reduce the edema by restoring BBB function. Other options such as conditions related to cytotoxic edema (e.g., ischemic stroke or traumatic brain injury) have not shown benefit from steroid use and may experience harm, as shown in studies like the CRASH trial for TBI.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-oncology",
    "explanation": "Corticosteroids, such as dexamethasone, are anti-inflammatory agents that work by stabilizing cell membranes and reducing vascular permeability. This is particularly relevant in cases of vasogenic edema, where the blood\u2013brain barrier (BBB) is disrupted, causing fluid leakage from capillaries into the interstitial brain tissue. Vasogenic edema, commonly seen in brain tumors (e.g., primary brain cancer or metastases), occurs when the integrity of the BBB is compromised, leading to extravasation of plasma proteins and water into the extracellular space. Steroids help restore the BBB integrity via anti\u2010inflammatory pathways and by reducing cytokine production, thereby diminishing the edema. In contrast, in conditions with cytotoxic edema (such as ischemic stroke), the intracellular swelling results from energy failure, and steroids have not been shown to be effective and may even be harmful. Patients with brain cancers often develop symptoms such as headache, nausea, and focal neurological deficits attributable to increased intracranial pressure and mass effect from edema. Administration of steroids can rapidly relieve these symptoms by decreasing the volume of vasogenic edema, thus improving clinical status temporarily or as a bridge to definitive treatment. Diagnosis involves neuroimaging \u2013 CT or MRI demonstrating a mass with surrounding vasogenic edema. Differential considerations include brain abscess, hemorrhage, and other intracranial neoplasms. Radiographic features such as irregular margins, contrast enhancement, and edema help differentiate tumor-associated edema from other types. First-line management for vasogenic edema associated with brain tumors is high-dose corticosteroids (e.g., dexamethasone). Second-line measures might involve osmotic agents like mannitol for severe raised intracranial pressure. In pregnant or lactating patients, the use of corticosteroids is carefully balanced against potential risks; however, dexamethasone is often used when benefits outweigh risks, with multidisciplinary consultation including obstetrics. Option A (brain cancer with vasogenic edema) is correct because steroids effectively reduce the edema by restoring BBB function. Other options such as conditions related to cytotoxic edema (e.g., ischemic stroke or traumatic brain injury) have not shown benefit from steroid use and may experience harm, as shown in studies like the CRASH trial for TBI. 1. Dexamethasone is the steroid of choice for reducing vasogenic edema in brain tumors. 2. Steroids are ineffective in treating cytotoxic edema and may worsen outcomes in ischemic stroke. 3. Rapid symptomatic improvement in brain tumor patients can be achieved by reducing vasogenic edema. Recent guidelines and clinical experience affirm the utility of steroids in reducing vasogenic edema associated with neoplasms. Trials such as those assessing steroid use in brain tumors continue to support their role for symptomatic management, while studies like the CRASH trial reiterate that steroids have a detrimental effect in traumatic brain injury and ischemic stroke.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Question of mets only to the dura and skull will happen with what of the following?",
    "option_a": "Prostate cancer (bradly)",
    "option_b": "Breast cancer > prostate > lung > head and neck > a hematological (other sources)",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Metastatic spread to the dura and skull occurs via hematogenous dissemination, direct extension, or venous spread, and certain cancers have a predilection for metastasizing to these sites. Breast cancer cells, along with other cancers such as prostate and lung, can metastasize to the skull and dura. These metastases develop when cancer cells seed in the diploic veins or through direct extension from adjacent bone lesions. The tumor microenvironment in these tissues facilitates the establishment of secondary deposits. Patients with metastases to the dura or skull might present with focal neurological deficits, headache, or localized pain over the skull. Imaging studies such as MRI and CT may reveal bone lesions and dural thickening. The clinical signs depend on the location and extent of the metastatic spread. Differential diagnoses include meningioma (which can mimic dural-based lesions), primary bone tumors, and inflammatory conditions. Radiologic features with contrast-enhanced MRI or CT help differentiate metastases from primary intracranial neoplasms, as metastases tend to be multiple and associated with bony destruction. Management is typically multidisciplinary, involving systemic therapy (hormonal therapy, chemotherapy, targeted agents) tailored to the primary cancer type, radiotherapy (local or whole-brain if indicated), and sometimes surgical resection for symptomatic relief. In pregnant or lactating women, treatment involves careful selection of therapies that minimize fetal and neonatal risks, with consultation from oncology and maternal-fetal medicine specialists. Option B (Breast cancer > prostate > lung > head and neck > a hematological malignancy) is correct because epidemiological data consistently indicate that breast cancer metastasizes to the dura and skull more frequently than other cancers, although prostate cancer also contributes significantly. This ordering is supported by multiple studies and cancer registry data. 1. Breast cancer is the most common source of dural and skull metastases. 2. A high index of suspicion is necessary when a patient with a known primary malignancy presents with new neurological symptoms or skull pain. 3. Imaging with contrast-enhanced MRI is critical for diagnosis. Contemporary reviews and cancer registries underscore the prevalence of breast cancer metastases to the dura and skull. Updated treatment guidelines emphasize early multidisciplinary intervention and tailored systemic therapy based on the primary tumor's biology.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Coronal brain MRI showing frontal extra axial homogeneous mass, Histopathology?",
    "option_a": "Psammoma bodies (Meningioma)",
    "option_b": "Pseudopalisading",
    "option_c": "Neovascularization",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Meningiomas are typically benign, extra-axial tumors arising from the meningothelial (arachnoid cap) cells. They characteristically present as well-circumscribed, homogeneous masses on neuroimaging. The development of meningiomas is related to proliferative changes in arachnoid cells, with a well-known association with radiation exposure and, in some cases, with genetic syndromes such as neurofibromatosis type 2. Histologically, many meningiomas exhibit psammoma bodies, which are concentrically calcified structures. Clinically, meningiomas often present with slowly progressive focal neurologic deficits, seizures, or signs of raised intracranial pressure depending on size and location. Their extra-axial location contributes to a classic imaging appearance with a \u2018dural tail\u2019 sign on MRI. The diagnosis of meningioma is established by imaging \u2013 typically contrast-enhanced MRI \u2013 and confirmed by histopathological examination. Differential diagnoses include schwannomas, hemangiopericytomas, and metastatic lesions. Histopathology demonstrating psammoma bodies strongly supports the diagnosis of meningioma. First-line treatment for symptomatic meningiomas is surgical resection. Observation is an option for small, asymptomatic tumors. Radiotherapy can be considered for residual, recurrent, or inoperable cases. In pregnancy, surgical intervention is deferred if possible, and timing is carefully planned to minimize risks to the fetus; radiotherapy is generally contraindicated unless absolutely necessary. Option A, referencing psammoma bodies present in a meningioma, is correct. Other options such as pseudopalisading (characteristic of glioblastoma multiforme) and neovascularization (often seen in high-grade gliomas) do not correlate with the classic histologic features of meningiomas. 1. Meningiomas are the most common extra-axial brain tumors and are more frequent in women. 2. The presence of psammoma bodies is a histologic hallmark of many benign meningiomas. 3. A dural tail sign on MRI is suggestive, though not diagnostic, of meningioma. Recent guidelines continue to support the surgical resection of symptomatic meningiomas, with adjuvant radiotherapy for non-resectable or high-grade lesions. Advances in molecular pathology are beginning to refine classification and predict behavior more accurately.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_31.png"
  }
]